Abbott LaboratoriesvsCaris Life Sciences

ABT and CAI stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$104.48

Value $182B

-0.22%
ABT's page

CAI

Caris Life Sciences, Inc.

$19.50

Value $5.5B

-2.21%
CAI's page

Abbott Laboratories (ABT) has a market value of $182B and Caris Life Sciences (CAI) $5.5B. Over the last year, with dividends, ABT moved -17.7% and CAI -17.8%. The P/E is 38.6 for ABT and 57.4 for CAI. Dividend yield: ABT 2.41%, CAI none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$182B

    CAI$5.5B

    ABT is 33 times CAI

  • Revenue, 12 months

    ABT$48.2B

    CAI$1.0B

    ABT is 46 times CAI

  • Net income, 12 months

    ABT$4.7B

    CAI$96M

    ABT is 49 times CAI

  • Operating margin

    ABT13.8%

    CAI13.4%

    0.4 points apart

  • ROIC

    ABT6.3%

    CAI11.5%

    5.2 points apart

  • P/E

    ABT38.6

    CAI57.4

    CAI is 1.5 times ABT

  • Dividend yield

    ABT2.4%

    CAI0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-17.7%

CAI-17.8%

75100125DecFebAprJunAugOct
Returns by period
PeriodABTWith dividendsCAIWith dividends
1 year since November 17, 2025-17.7%Price -19.6%-17.8%Price -17.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesCAICaris Life Sciences

Valuation

ABTCAI
Valuation
Price$104.48$19.50
Market value$182B$5.5B
Enterprise value (EV)$208B–
P/E38.657.4
P/E, 5-year median33.7–
P/B3.68.6
EV/EBIT31.4–
Free cash flow yield3.7%0.5%

Results and growth

ABTCAI
Results and growth
Revenue, 12 months$48.2B$1.0B
Net income, 12 months$4.7B$96M
Free cash flow, 12 months$6.8B$29M
Earnings per share, 12 months$2.69$0.34
Revenue growth, year on year5.7%97.0%
Revenue growth a year, past+5.1%over 5 years+62.9%over 2 years
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTCAI
Margins and returns on capital
Gross margin56.9%–
Operating margin13.8%13.4%
Net margin9.8%9.2%
ROIC6.3%11.5%
ROE9.1%16.7%

Balance sheet

ABTCAI
Balance sheet
Cash$4.3B–
Total debt$31.2B–
Net debt / EBITDA3.3–
Interest cover6.7×3.3×

Dividends and buybacks

ABTCAI
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%0.0%
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or CAI

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Caris Life Sciences?

By market value, Abbott Laboratories ($182B) is about 32.9 times Caris Life Sciences ($5.5B), at today's prices.

How did ABT and CAI stock do over the last 1 years?

Since November 17, 2025, ABT's price moved -19.6% and CAI's -17.8%. With dividends: ABT -17.7% (-17.7% a year), CAI -17.8% (-17.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or CAI?

The dividend yield at today's price is 2.41% for Abbott Laboratories and none for Caris Life Sciences. Over the last twelve months they paid $2.52 and – per share.

What is the P/E of ABT and CAI?

At today's price, the P/E is 38.6 for ABT and 57.4 for CAI. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Abbott Laboratories or Caris Life Sciences?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 9.2% for Caris Life Sciences, and the operating margin 13.8% and 13.4%. Revenue was $48.2B and $1.0B.

Which is the better investment, Abbott Laboratories or Caris Life Sciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.